Sign in to follow
Search Results

0 results for 'Roche Holding Ltd'

You can use to get even better search results
April 30, 2008 |

Unpublished Opinions

Unpublished state and federal court opinions.
52 minute read
March 14, 2006 |

Patent Injunctions

Peter J. Pizzi, a partner at Connell Foley, writes that fanfare about patents essential to tens of thousands of Blackberry users may spur a dialogue about public interest factors courts are to consider in deciding whether to grant an injunction against patent infringement. Such debate is particularly timely given that the U.S. Supreme Court will soon weigh in on the subject in a patent case on its docket
11 minute read
October 09, 2012 |

Daily Decision Service Alert: Vol. 21, No. 197 – October 9, 2012

Daily decision alert.
11 minute read
February 26, 2013 |

The Am Law 100, the Early Numbers: Amid Partner Growth Spurt, Weil's Profits Drop

A year that saw Weil, Gotshal & Manges expand its partnership ranks significantly ended with the firm's gross revenues essentially flat at $1.229 billion and its profits per partner down 8.6 percent to $1.86 million, according to The American Lawyer's reporting.
4 minute read
Law Journal Press | Digital Book Federal Bank Holding Company Law Authors: Melanie L. Fein View this Book

View more book results for the query "Roche Holding Ltd"

April 13, 2006 |

Publishing Clinical Trial Data Could Affect Patents

Imagine that a company marketing a new drug ran tests that showed a kidney failure risk, but didn't make the risk public. Now imagine there's a law that would force the drug company to tell the public about every test it conducted on the drug. If certain policymakers and interest groups get their way, such a law could soon become a reality. While this may be a boon for doctors and patients alike, pharmaceutical companies need to keep a watchful eye on how this could affect their patent rights.
9 minute read
July 07, 2003 |

Preclinical use of research tool is infringement

The biotechnology industry has been given new life, and the drug pipeline can keep flowing. In a case of first impression closely watched by the biotechnology and pharmaceutical industries, the U.S. Court of Appeals for the Federal Circuit held on June 6, in Integra Lifesciences I Ltd. v. Merck KGaA, nos. 02-1052, 02-1065, 2003 U.S. App. Lexis 11335 (Fed. Cir. June 6, 2003), that preclinical use of a patented research tool for drug discovery is patent infringement and is not protected under the safe harbor
10 minute read
December 19, 2007 |

Unpublished Opinions

Unpublished state and federal court opinions.
35 minute read
March 06, 2008 |

Unpublished Opinions

Unpublished state and federal court opinions.
54 minute read

More from ALM

More from ALM

Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

Resources

  • Good Legal Technology is Good Business: A Case for Bringing Employment Issues In-House

    Brought to you by LexisNexis®

    Download Now

  • Insights and Strategies for Effective Succession Planning in AM Law 100 Firms

    Brought to you by Gallagher

    Download Now

  • State AI Legislation Is on the Move in 2024

    Brought to you by LexisNexis®

    Download Now

  • 2024 ESI Risk Management & Litigation Readiness Report

    Brought to you by Pagefreezer

    Download Now

NEXT